First Quadrant’s Pacira BioSciences PCRX Stock Holding History

First Quadrant’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$47K	Sell	610 -41	-6%	-$2.73K	0.26%	16
2021 Q4	$39K	Buy	+651	New	+$35.9K	﹤0.01%	432
2019 Q3	–	Sell	-6,093	Closed	-$265K	–	654
2019 Q2	$265K	Sell	6,093 -2,780	-31%	-$118K	0.02%	486
2019 Q1	$338K	Buy	8,873 +1,316	+17%	+$51.4K	0.03%	417
2018 Q4	$325K	Buy	+7,557	New	+$353K	0.03%	432

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

First Quadrant's PCRX Position: Q1 2022 in Review

First Quadrant reduced its Pacira BioSciences (PCRX) stake by 6.3% in Q1 2022, selling an estimated $2.73K and leaving 610 shares worth $47K. The position accounts for 0.26% of the portfolio, ranked #16.

First Quadrant first reported a position in PCRX in Q4 2018 and has held it in 5 quarters since. The position peaked at $338K in Q1 2019. 301 funds tracked by Wall St. Rank hold PCRX as of Q1 2022.

First Quadrant held 610 shares of Pacira BioSciences worth $47K as of Q1 2022.
First Quadrant sold 41 Pacira BioSciences shares in Q1 2022, an estimated $2.73K.
Pacira BioSciences made up 0.26% of First Quadrant's portfolio in Q1 2022, its #16 holding.
First Quadrant first reported a position in Pacira BioSciences in Q4 2018 and has held it in 5 quarters since.
First Quadrant's Pacira BioSciences position peaked at $338K in Q1 2019.
301 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2022.

Based on First Quadrant's 13F filing for Q1 2022, filed 21 Apr 2022.